PDX Pharmaceuticals is a biotechnology company that specializes in the development of innovative therapies for various forms of cancer. Founded in 2010 as a start-up from the Biomedical Engineering Department at Oregon Health and Science University School of Medicine, PDX Pharma has raised a total of $11 million in funding to date, with $7. 8 million being non-dilutive.

Currently, the company is seeking private investment to conduct clinical trials for its first drug candidate, ARAC. The mission of PDX Pharmaceuticals is to improve human health and medicine through the use of nanotechnology and cancer systems biology. They develop novel therapeutics using their patented nanoparticle platform (Pdx-NP TM), which enables the co-delivery of siRNA, drugs, vaccines, and immunotherapies.

Their focus is on nano-based combination immunotherapeutics that address unmet needs in cancer treatment. Located at OHSU's Center for Health and Healing in Portland, Oregon, PDX Pharmaceuticals now also has an office and lab space at the Oregon Bioscience Incubator. They specialize in the development of animal models of cancer for in vivo efficacy and safety evaluation of their drug candidates.

Additionally, they have expertise in combination therapies and precision medicine in cancer, working in collaboration with the Knight Cancer Institute of OHSU. PDX Pharma has been recognized for its accomplishments, receiving a two-year $1. 87 million phase II SBIR grant from the National Cancer Institute for the development of ARAC-02, a novel lung cancer treatment.

Their ARAC-02 drug candidate has also been selected for the Nanotechnology Characterization Lab's collaboration and characterization program. Furthermore, they have won two Corporate Philanthropy Awards. With over 60 peer-reviewed publications and six journal-covered articles, PDX Pharmaceuticals is a leader in the field of advanced functional materials and nanotechnology.

Their patented drug candidates have the ability to overcome resistance of current targeted therapies and trigger a cancer-specific immune response. By combining nanotechnology with cancer systems biology, PDX Pharma strives to revolutionize cancer treatment and improve patient outcomes